A Phase I, Randomized, Single-Blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 Following Single and Multiple Ascending Dose Administration to Healthy Subjects With or Without Elevated LDL-C Levels
Latest Information Update: 24 Jul 2024
At a glance
- Drugs AZD 0780 (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
Most Recent Events
- 19 Jul 2024 Status changed from active, no longer recruiting to completed.
- 13 Jun 2024 Planned End Date changed from 10 Jun 2024 to 14 Jun 2024.
- 13 Jun 2024 Planned primary completion date changed from 23 May 2024 to 14 Jun 2024.